CoChat

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data

Durairaj, Ashwin, Sabates, Alberto, Nieves, Jonathan, Moraes, Brian, Baum, Seth · 2017 · Current Treatment Options in Cardiovascular Medicine

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

Abstract

Opinion statement Atherosclerotic cardiovascular disease (ASCVD) remains the number one killer in the western world. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and ezetimibe has been shown to reduce the risk of cardiovascular events. Now, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mabs) are available for high-risk individuals with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy but requiring greater LDL-C reduction. PCSK9 mab outcome trial results from the Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk (FOURIER) study, which was presented at the American College of Cardiology in March 2017, which demonstrated a decrease of 15% in primary and 20% secondary end points over a 2-year period [1••]. These results firmly demonstrated additional benefit beyond maximally tolerated statin therapy in high-risk individuals. Thus, management of LDL-C will soon become more complex, as a new class of medication is added to our standard armamentarium. This review explores the discovery of PCSK9, its biology and physiology, and the development of the PCSK9 mabs.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11936-017-0556-0

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Cited by

See all 27

Metadata

Authors
Durairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S.
Affiliations
  • Florida Atlantic University (US)
  • Nova Southeastern University (US)
Corresponding author
Durairaj, Ashwin
Venue
Current Treatment Options in Cardiovascular Medicine
Published
2017-06-22
Volume
19
Issue
8
Pages
58-58
ISSN
  • 1092-8464 (ISSN-L)
  • 1534-3189
OpenAlex
W2629389075
Cited by
27
References
54
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 5 · 2018: 1 · 2017: 1
FWCI
0.64
Type
journal article
Language
en
Open access
closed
Locations
  • Current Treatment Options in Cardiovascular Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
PCSK9, PCSK9 inhibitors, PCSK9 monoclonal antibodies, LDL cholesterol lowering, atherosclerotic cardiovascular disease, familial hypercholesterolemia, statin therapy, FOURIER trial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. https://app.cochat.ai/papers/10.1007/s11936-017-0556-0
The paper
Durairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. Current Treatment Options in Cardiovascular Medicine. https://doi.org/10.1007/s11936-017-0556-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.